There Is Progress At PAVmed, But More Patience Is Required

  • The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage.
  • Yet, like for most pre-revenue medical device companies, the pandemic has complicated things quite a lot and by the looks of it, might well do so again.
  • We still like the company longer-term though but this is one to slowly accumulate on dips, there are likely to be some of these left.
  • This idea was discussed in more depth with members of my private investing community, SHU Growth Portfolio. Get started today »